Jing Zhang
Vice President, Head, Discovery D3 Blo
Seminars
Wednesday 17th September 2025
D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, & Demonstrates Robust Preclinical & Clinical Activities
1:30 pm
- The discovery journey of D3S-001 and the unique target engagement kinetics of this nextgeneration KRAS G12C inhibitor
- How its novel mode of action enables the compound to overcome EGF-mediated nucleotide exchange and some of the known resistance mechanisms
- Translating the preclinical features of D3S-001 into the clinic and exploring combination strategies with internal assets (novel IO bispecific antibody and small molecule) to enhance anti-tumor activity and overcome resistance
